Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Capital Employed (2022 - 2026)

Axsome Therapeutics' Return on Capital Employed history spans 5 years, with the latest figure at 17.09% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 6272.0% to 17.09% in Q1 2026 year-over-year; TTM through Mar 2026 was 17.09%, a 6272.0% increase, with the full-year FY2025 number at 15.37%, up 6519.0% from a year prior.
  • Return on Capital Employed hit 17.09% in Q1 2026 for Axsome Therapeutics, down from 12.8% in the prior quarter.
  • Over the last five years, Return on Capital Employed for AXSM hit a ceiling of 12.8% in Q4 2025 and a floor of 85.38% in Q3 2024.
  • Historically, Return on Capital Employed has averaged 61.11% across 5 years, with a median of 70.7% in 2024.
  • Biggest five-year swings in Return on Capital Employed: tumbled -4602bps in 2024 and later soared 7098bps in 2025.
  • Tracing AXSM's Return on Capital Employed over 5 years: stood at 75.34% in 2022, then soared by 32bps to 50.87% in 2023, then crashed by -65bps to 83.78% in 2024, then skyrocketed by 85bps to 12.8% in 2025, then crashed by -34bps to 17.09% in 2026.
  • Business Quant data shows Return on Capital Employed for AXSM at 17.09% in Q1 2026, 12.8% in Q4 2025, and 72.2% in Q3 2025.